Gene therapy for rheumatoid arthritis. Theoretical considerations

Drugs and Aging

Volumn 12, Issue 1, 1998, Pages 29-41

  Chernajovsky, Yuti ^a   Annenkov, Alex ^a   Herman, Charlotte ^a   Triantaphyllopoulos, Kostas ^a   Gould, David ^a   Dreja, Hanna ^a   Moyes, Sasha P ^a   Croxford, J Ludovic ^b   Mageed, Rizgar A ^a   Podhajcer, Osvaldo L ^c   Baker, David ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CYTOKINE; CYTOKINE RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN FRAGMENT; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; PLASMID DNA; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; VIRUS VECTOR;

CELL TYPE; CLINICAL TRIAL; COMPLEMENT SYSTEM; GENE TARGETING; GENE THERAPY; HUMAN; MAJOR CLINICAL STUDY; MEDIATOR; META ANALYSIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS;

ARTHRITIS, RHEUMATOID; GENE THERAPY; GENETIC VECTORS; HUMANS;

EID: 15644372743     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199812010-00004     Document Type: Review

References (135)

1. Feldmann M, Brennan FM, Abney ER, et al. Are imbalances in cytokine function of importance in the pathogenesis of rheumatoid arthritis? In: Davies ME, Dingle JT, editors. Immunopharmacology of joints and connective tissue. London: Academic Press, 1994: 119-28
2. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Ann Rev Immunol 1996; 14: 397-440
3. Deighton CM, Wentzel J, Cavanagh G, et al. Contribution of inherited factors to rheumatoid arthritis. Ann Rheum Dis 1992; 51: 182-5
4. Stastny P. Association of the B-cell alloantigen Drw4 with rheumatoid arthritis. N Engl J Med 1978; 298: 869-72
5. Winchester R. The molecular basis of susceptibility to rheumatoid arthritis. Adv Immunol 1994; 56: 389-450
6. Londei M. Persistence of collagen type II specific T cell clones in the synovial membrane of a patient with rheumatoid arthritis. Proc Natl Acad Sci U S A 1989; 86: 636-40
7. Gause A, Gundlach K, Zdichavsky M, et al. The B-lymphocyte in rheumatoid-arthritis - analysis of rearranged V-kappa genes from B-cells infiltrating the synovial-membrane. Eur J Immunol 1995; 25: 2775-82
8. Moyes SP, Brown CM, Scott BB, et al. Analysis of Vk genes in rheumatoid arthritis synovial B lymphocytes provides evidence for both polyclonal activation and antigen-driven selection. Clin Exp Immunol 1996; 105: 89-98
9. Hingorani R, Monteiro J, Furie R, et al. Oligoclonality of V-beta-3 TCR chains in the CD8(+) T-cell population of rheumatoid-arthritis patients. J Immunol 1996; 156: 852-8
10. Paliard X, West SG, Lafferty JA, et al. Evidence for the effects of a superantigen in rheumatoid arthritis. Science 1991; 253: 325-9
11. Brennan FM, Chantry D, Jackson A, et al. Inhibitory effect of TNF antibodies on synovial cell IL-1 production in rheumatoid arthritis. Lancet 1989; 11: 244-7
12. Haworth C, Brennan FM, Chantry D, et al. Expression of granulocyte-macrophage colony stimulating factor (GM-CSF) in rheumatoid arthritis: regulation by tumour necrosis factor alpha. Rheumatol Int 1991; 11: 45-50
13. McInnes IB, Leung BP, Sturrock RD, et al. IL-15 mediates T cell-dependent regulation of TNFα production in rheumatoid arthritis. Nat Med 1997; 3: 189-95
14. Holmdahl R, Jansson L, Larsson E, et al. Homologous type II collagen induces chronic and progressive arthritis in mice. Arthritis Rheum 1986; 29: 106-13
15. Holmdahl R, Mo J, Nordling C, et al. Collagen induced arthritis: an experimental model for rheumatoid arthritis with involvement of both DTH and immune complex mediated mechanisms. Clin Exp Rheumatol 1989; 7 Suppl. 3: 51-5
16. Courtenay JS, Dallman MJ, Dayan AD, et al. Immunisation against type II collagen induces arthritis in mice. Nature 1980; 283: 665-8
17. Elliott M, Maini RN, Feldmann M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to TNF alpha. Arthritis Rheum 1993; 36: 1681-9
18. Elliott MJ, Maini RN, Feldmann M, et al. Randomised double blind comparison of a chimaeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344: 1105-10
19. Seki N, Sudo Y, Yoshioka T, et al. Type II-induced murine arthritis. I. Induction and preparation of arthritis require synergy between humoral and cell mediated immunity. J Immunol 1988; 140: 1477-84
20. Nabozny GH, Baisch JM, Cheng S, et al. HLA-DQ8 transgenic mice are highly susceptible to collagen-induced arthritis: a novel model for human polyarthritis. J Exp Med 1996; 183: 27-37
21. d transgene on collagen-induced arthritis. J Exp Med 1994; 180: 1559-64
22. Mori L, Loetscher H, Kakimoto K, et al. Expression of a transgenic T cell receptor beta chain enhances collagen-induced arthritis. J Exp Med 1992; 176: 381-8
23. Osman GE, Toda M, Kanagawa O, et al. Characterization of the T cell receptor repertoire causing collagen arthritis in mice. J Exp Med 1993; 177: 387-95
24. Banerjee S, Anderson GD, Luthra HS, et al. Influence of complement C5 and V-beta T cell receptor mutation on susceptibility to collagen-induced arthritis in mice. J Immunol 1989; 142: 2237-43
25. Keffer J, Probert L, Cazlaris H, et al. Transgenic mice expressing human TNF: a predictive genetic model of arthritis. EMBO J 1991; 10: 4025-31
26. McIntyre KW, Shuster DJ, Gillooly KM, et al. Reduced incidence and severity of collagen-induced arthritis in IL-12 deficient mice. Eur J Immunol 1996; 26: 2933-8
27. Hess H, Gately MK, Rüde E, et al. High doses of IL-12 inhibit the development of joint disease in DBA/1 mice immunized with type II collagen in complete Freund's adjuvant. Eur J Immunol 1996; 26: 187-91
28. Williams RO, Mason EJ, Feldmann M, et al. Synergy between anti-CD4 and anti-TNF in the amelioration of established collagen-induced arthritis. Proc Natl Acad Sci U S A 1994; 91: 2762-6
29. Williams RO, Feldmann M, Maini RN. Anti-TNF ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci U S A 1992; 89: 9784-8
30. Kasama T, Strieter RM, Lukacs NW, et al. IL-10 expression and chemokine regulation during the evolution of murine type I collagen-induced arthritis. J Clin Invest 1995; 95: 2868-76
31. Durie FH, Fava RA, Foy TM, et al. Prevention of collagen induced arthritis with an antibody to gp39, the ligand to CD40. Science 1993; 261: 1328-30
32. Webb L, Walmsley MJ, Feldmann M. Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 costimulatory pathway - requirement for both B7-1 and B7-2. Eur J Immunol 1996; 26: 2320-8
33. Mikecz K, Brennan FR, Kim JH, et al. Anti-CD44 treatment abrogates tissue oedema and leukocyte infiltration in murine arthritis. Nat Med 1995; 1: 558-63
34. Kavanaugh A, Nichols L, Davis L, et al. Anti-CD54 (ICAM-1) monoclonal antibody therapy in refractory rheumatoid arthritis [abstract]. Arthritis Rheum 1993; 36: S40
35. Ilgo Y, Takashi T, Tamatani T. ICAM-1 dependent pathway is critically involved in the pathogenesis of adjuvant arthritis. J Immunol 1991; 147: 4167-71
36. Plater-Zyberk C, Bonnefoy J-Y. Marked amelioration of established collagen-induced arthritis by treatment with antibodies to CD23 in vivo. Nat Med 1995; 1: 781-5
37. Wang Y, Rollins SA, Madri JA, et al. Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease. Proc Natl Acad Sci U S A 1995; 92: 8955-9
38. Malfait A-M, Butler D, Presky DH, et al. Blockade of IL-12 during the induction of collagen-induced arthritis markedly attenuates the severity of the arthritis. Clin Exp Immunol. In press
39. Lens JW, van der Bers WB, van de Putte LB, et al. Flare-up of antigen induced arthritis in mice after challenge with intravenous antisera: effects of pretreatment with cobra venom factor and anti-lymphocyte antiserum. Clin Exp Immunol 1984; 3: 520-8
40. Lanzavechia A. Identifying strategies for immune intervention. Science 1993; 260: 937-44
41. Lifely MR, Hale C, Boyce S, et al. Glycosylation and biological activity of CAMPATH-1H expressed in different cell lines and grown under different culture conditions. Glycobiology 1995; 5: 813-22
42. Gossen M, Freundlieb S, Bender G, et al. Transcriptional activation by tetracyclines in mammalian cells. Science 1995; 268: 1766-9
43. Bohl D, Naffakh N, Heard J-M. Long-term control of erythropoietin secretion by doxycycline in mice transplanted with engineered primary myoblasts. Nat Med 1997; 3: 299-305
44. Colcher D, Bird R, Roselli M, et al. In vivo tumor targeting of a recombinant single-chain antigen-binding protein. J Natl Cancer Inst 1990; 82: 1191-7
45. Yokota T, Milenic DE, Whitlow M, et al. Rapid tumor penetration of single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 1992; 52: 3402-8
46. McCafferty J, Griffiths AD, Winter G, et al. Phage antibodies: filamentous phage displaying antibody variable domains. Nature 1990; 348: 552-4
47. Deshane J, Grim J, Feng M, et al. Targeted eradication of erbB-2 over-expressing tumor-cells employing expression of an intracellular antibody-directed against the erbB-2 oncoprotein [abstract]. Eur J Cancer 1995; 31a: 21
48. Biocca S, Cattanea A. Intracellular immunization: antibody targeting to subcellular compartments. Trends Cell Biol 1995; 5: 248-52
49. Speiser DE, Sebzda E, Ohteki T, et al. Tumor necrosis factor receptor p55 mediates deletion of peripheral cytotoxic T lymphocytes in vivo. Eur J Immunol 1996; 26: 3055-60
50. Williams RO, Ghrayeb J, Feldmann M, et al. Successful therapy of collagen induced arthritis with TNF receptor-IgG fusion protein and combination with anti-CD4. Immunology 1995; 84: 433-9
51. Baker D, Butler D, Scallon BJ, et al. Control of established EAE by inhibition of TNF activity within the CNS using monoclonal antibodies and TNF receptor-immunoglobulin fusion proteins. Eur J Immunol 1994; 24: 2040-8
52. Moreland LW, Margolies G, Heck Jr LW, et al. Recombinant soluble TNF-R (p80) fusion protein: toxicity and dose finding trial in refractory rheumatoid arthritis. J Rheumatol 1996; 23: 1849-55
53. Peppel K, Crawford D, Beutler B. A TNF receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity. J Exp Med 1991; 174: 1483-9
54. Bemelmans MHA, Gouma DJ, Buurman WA. Influence of nephrectomy on TNF receptor clearance in a murine model. J Immunol 1993; 150: 2007-17
55. Nophar Y, Kemper O, Brakebusch C, et al. Soluble forms of tumour necrosis factor receptors (TNF-Rs): the cDNA for type 1 TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor. EMBO J 1990; 9: 3269-78
56. Chernajovsky Y, Adams G, Podhajcer O, et al. Inhibition of transfer of collagen-induced arthritis into SCID mice by ex vivo infection of spleen cells with retroviruses expressing soluble human TNF receptor. Gene Ther 1995; 2: 731-5
57. Neve R, Kissonerghis M, Feldmann M, et al. Expression of an efficient small molecular weight TNF/lymphotoxin antagonist. Cytokine 1996; 8: 365-70
58. Chernajovsky Y. Systemic gene therapy of arthritis. In: Robbins PD, Evans C, editors. Innovative therapies for rheumatoid arthritis. Barcelona: Prous Science. In press
59. Croxford JL, Baker D, Triantaphyllopoulos K, et al. Cytokine gene therapy in chronic relapsing experimental allergic encephalomyelitis [abstract]. Multiple Sclerosis 1996; 2: 20
60. Sioud M, Natvig JB, Forre O. Preformed ribozyme destroys tumor-necrosis-factor messenger RNA in human cells. J Mol Biol 1992; 223: 831-5
61. Sioud M. Interaction between tumor-necrosis-factor-alpha ribozyme and cellular proteins - involvement in ribozyme stability and activity. J Mol Biol 1994; 242: 619-29
62. Wooley PH, Whalen JD, Chapman DL, et al. The effect of an IL-1ra protein on type II collagen-induced arthritis and antigen-induced arthritis in mice. Arthritis Rheum 1993; 36: 1305-14
63. Hung GL, Galea-Lauri J, Mueller GM, et al. Suppression of intra-articular responses to IL-1 by transfer of the IL-1 receptor antagonist gene to synovium. Gene Ther 1994; 1: 64-9
64. Bandara G, Mueller GM, Galea-Lauri J, et al. Intraarticular expression of biologically active IL-1 receptor antagonist protein by ex vivo gene transfer. Proc Natl Acad Sci U S A 1993; 90: 10764-8
65. Makarov SS, Olsen JC, Johnston WN, et al. Suppression of experimental arthritis by gene-transfer of IL-1 receptor antagonist cDNA. Proc Natl Acad Sci U S A 1996; 93: 402-6
66. Otani K, Nita I, Macaulay W, et al. Suppression of antigen-induced arthritis in rabbits by ex vivo gene-therapy. J Immunol 1996; 56: 3558-62
67. Ghivizzani SC, Kang R, Hatton C, et al. In vivo delivery of genes encoding soluble receptors for IL-1 and TNF-alpha results in a synergistic therapeutic effect in antigen-induced arthritis in the rabbit knee [abstract]. Arthritis Rheum 1996; 39: S308
68. Evans CH, Robbins PD, Ghivizzani SC. Clinical trial to assess safety, feasibility, and efficacy of transferring a potentially anti-arthritic cytokine gene to human joints with rheumatoid arthritis. Hum Gene Ther 1996; 7: 1261-80
69. Symons JA, Young PR, Duff GW. Soluble type-ii interleukin-1 (IL-1) receptor binds and blocks processing of IL-1-beta precursor and loses affinity for IL-1 receptor antagonist. Proc Natl Acad Sci U S A 1995; 92: 1714-8
70. Mosmann TR, Coffman RL. Heterogeneity of cytokine secretion patterns and functions of helper T cells. Adv Immunol 1989; 46: 111-47
71. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996; 17: 138-46
72. D'Andrea A, Aste-Amezaga M, Valiante NM, et al. IL-10 inhibits human lymphocyte IFN-gamma-production by suppressing natural killer cell stimulatory factor IL-12 synthesis in accessory cells. J Exp Med 1993; 178: 1041-8
73. Walmsley M, Katsikis PD, Abney E, et al. Interleukin-10 inhibition of the progression of established collagen-induced arthritis. Arthritis Rheum 1996; 39: 495-503
74. Del Prete G, De Carli M, Almerigogna F, et al. Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production. J Immunol 1993; 150: 353-60
75. Perez L, Orte J, Brieva JA. Terminal differentiation of spontaneous rheumatoid factor-secreting B cells from rheumatoid arthritis patients depends on endogenous IL-10. Arthritis Rheum 1995; 38: 1771-6
76. Bessis N, Boissier MC, Caput D, et al. Cytokine gene-therapy using IL-4 and IL-13 in murine collagen-induced arthritis [abstract]. Clin Res 1994; 42: A135
77. Bessis N, Boissier MC, Ferrara P, et al. Attenuation of collagen-induced arthritis in mice by treatment with vector cells engineered to secrete IL-13. Eur J Immunol 1996; 26: 2399-403
78. Hesse M, Bayrak S, Mitchison A. Protective major histocompatibility complex genes and the role of IL-4 in collagen induced arthritis. Eur J Immunol 1996; 26: 3234-7
79. Erb KJ, Rüger B, von Brevern M, et al. Constitutive expression of IL-4 in vivo causes autoimmune-type disorders in mice. J Exp Med 1997; 185: 329-39
80. Lewis DB, Liggitt HD, Effmann EL, et al. Osteoporosis induced in mice by overproduction of IL-4. Proc Natl Acad Sci U S A 1993; 90: 11618-22
81. Marcelleti JF, Katz DH. Collagen-induced arthritis in mice: relationship of collagen-specific and total IgE synthesis to disease. J Immunol 1991; 147: 4185-91
82. Shull MM, Ormsby I, Kier AB, et al. Targeted disruption of the mouse TGF-beta1 gene results in multifocal inflammatory disease. Nature 1992; 359: 693-9
83. Arsura M, Wu M, Soneshein G. TGF b1 inhibits NF-kB/Rel activity inducing apoptosis of B cells: transcriptional activation of IkBa. Immunity 1996; 5: 31-40
84. Fontana A, Constam DB, Frei K, et al. Modulation of the immune response by TGF beta. Int Arch Allergy Immunol 1992; 99: 1-7
85. Günther M, Haubeck H-D, van de Leur E, et al. TGFb1 regulates TIMP-1 expression in differentiated articular chondrocytes. Arthitis Rheum 1994; 37: 395-405
86. Morales TI, Roberts AB. TGF beta regulates the metabolism of proteoglycans in bovine cartilage organ cultures. J Biol Chem 1988; 263: 12828-31
87. Derynck R. Structure of TGF alpha and beta and their precursors. In: Guroff G, editor. Oncogenes, genes and growth factors. New York: Academic Press, 1987: 133-63
88. Barcellos-Hoff MH, Derynck R, Tsang ML, et al. TGF beta activation in irradiated murine mammary gland. J Clin Invest 1994; 93: 892-9
89. Brandes ME, Allen JB, Ogawa Y, et al. TGF beta1 suppresses acute and chronic arthritis in experimental animals. J Clin Invest 1991; 87: 1108-13
90. Kuruvilla AP, Shah R, Hochwald GM, et al. Protective effect of TGF beta1 on experimental autoimmune diseases in mice. Proc Natl Acad Sci U S A 1991; 88: 2918-21
91. Allen JB, Manthey CL, Hand AR, et al. Rapid onset synovial inflammation and hyperplasia induced by transforming growth factor b. J Exp Med 1990; 171: 231-47
92. Raz E, Dudler J, Lotz M, et al. Modulation of disease activity in murine lupus erythematosus by cytokine gene delivery. Lupus 1995; 4: 286-92
93. Giladi E, Raz E, Karmeli F, et al. TGFb gene therapy ameliorates experimental colitis in rats. Eur J Gastroenterol Hepatol 1995; 7: 341-7
94. Chernajovsky Y, Adams G, Triantaphyllopoulos K, et al. Pathogenic lymphoid cells engineered to express TGF beta 1 ameliorate disease in a collagen-induced arthritis model. Gene Ther 1997; 4: 553-9
95. Mihara M, Ikuta M, Koishihara Y, et al. IL-6 inhibits delayed-type hypersensitivity and the development of adjuvant arthritis. Eur J Immunol 1991; 21: 2327-31
96. Aderka D, Le J, Vilcek J. IL-6 inhibits LPS-induced TNF production in cultured human monocytes, U937 cells, and in mice. J Immunol 1989; 143: 3517-23
97. Schindler R, Mancilla J, Endres S, et al. Correlations and interactions in the production of IL-6, IL-1 and TNF in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF. Blood 1990; 75: 40-7
98. Tilg H, Trehu E, Atkins MB, et al. IL-6 as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble TNF receptor p55. Blood 1994; 83: 113-8
99. Lotz M, Guerne P-A. Interleukin-6 induces synthesis of tissue inhibitor of metalloproteinases. J Biol Chem 1991; 266: 2017-20
100. Devajyothi C, Kalvakolanu I, Babcock GT, et al. Inhibition of IFN gamma-induced MHC class II gene transcription by IFN beta and TGF beta1 in human astrocytoma cells. J Biol Chem 1993; 268: 18794-800
101. Fearon DT, Carter RH. The CD19/CR2/tapa-1 complex of B lymphocytes: linking natural to acquired immunity. Ann Rev Immunol 1995; 13: 127-49
102. Weisman HF, Bartow T, Leppo MK, et al. Soluble human complement receptor 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 1990; 249: 146-51
103. Mulligan R. The basic science of gene therapy. Science 1993; 260: 926-32
104. Riddel SR, Elliott M, Lewinsohn DA, et al. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med 1996; 2: 216-3
105. Dai Y, Schwarz EM, Gu D, et al. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci U S A 1995; 92: 1401-5
106. Wilson JM. Adenoviruses as gene delivery vehicles. N Engl J Med 1996; 334: 1185-7
107. Takeuchi Y, Porter CD, Strahan KM, et al. Sensitization of cells and retroviruses to human serum by (alpha-1-3) galactosyl transferase. Nature 1996; 379: 85-8
108. Naldini L, Blömer U, Gallay P, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996; 272: 263-7
109. Nilson B, Morling FJ, Cosset FL, et al. Targeting of retroviral vectors through protease-substrate interactions. Gene Ther 1996; 3: 280-6
110. Cosset FL, Morling FJ, Takeuchi Y, et al. Retroviral retargeting by envelopes expressing an N-terminal binding domain. J Virol 1995; 69: 6314-22
111. Cosset FL, Russell SJ. Targeting retrovirus entry. Gene Ther 1996; 3: 946-56
112. Kozarsky KF, Wilson JM. Gene therapy: adenovirus vectors. Curr Opin Genet Dev 1993; 3: 499-503
113. Gorziglia MI, Kadan MJ, Yei S, et al. Elimination of both E1 and E2a from adenovirus vectors further improves prospects for in vivo human gene therapy. J Virol 1996; 70: 4173-8
114. Flotte TR, Carter BJ. Adeno-associated virus vectors for gene therapy. Gene Ther 1995; 2: 357-62
115. Chernajovsky Y, Feldmann M, Maini RN. Gene therapy of rheumatoid arthritis via cytokine regulation: future perspectives. Br Med Bull 1995; 51: 503-16
116. Xiang Z, Ertl HCJ. Manipulation of the immune response to a plasmid encoded viral antigen by co-inoculation with plasmids expressing cytokines. Immunity 1995; 2: 129-35
117. Hsu C-H, Chua K-Y, Tao M-H, et al. Immunoprophylaxis of allergen-induced IgE synthesis and airway hyperresponsiveness in vivo by genetic immunization. Nat Med 1996; 2: 540-4
118. Nabel GJ, Gordon D, Bishop DK, et al. Immune response in human melanoma after transfer of an allogeneic class I MHC gene with DNA-liposome complexes. Proc Natl Acad Sci U S A 1996; 93: 15388-93
119. Hakim I, Levy S, Levy R. A nine amino acid peptide from IL-1beta augments antitumor immune responses induced by protein and DNA vaccines. J Immunol 1996; 157: 5503-11
120. Makurov SS, Baldwin AS. Local suppression of NFkB inhibits experimental arthritis in rats [abstract]. Arthritis Rheum 1996; 39: 563
121. Tomita T, Hashimoto H, Tomita N, et al. Potential gene therapy tor rheumatoid arthritis - transfection of NFkB decoy inhibited production of interleukin-1 from synovial tissue of patients with rheumatoid arthritis [abstract]. Arthritis Rheum 1996; 39: 577
122. Makarov SS, Johnston WN, Olsen JC, et al. Gene-transfer of IkBα inhibits inflammatory responses in monocytic and stromal cells [abstract]. J Leukoc Biol 1996; 289
123. Wrighton CJ, Hofer-Warbinek R, Moll T, et al. Inhibition of endothelial cell activation by adenovirus-mediated expression of IkBa, an inhibitor of the transcription factor NF-kB. J Exp Med 1996; 183: 1013-22
124. Neurath MF, Pettersson S, Meyer zum Büschenfelde K-H, et al. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kB abrogates established experimental colitis in mice. Nat Med 1996; 2: 998-1004
125. Bandara G, Robbins PD, Georgescu HI, et al. Gene transfer to synoviocytes: prospects for gene treatment of arthritis. DNA Cell Biol 1992; 11: 227-31
126. Makarov SS, Olsen JC, Johnston WN, et al. Retrovirus-mediated in vivo gene-transfer to synovium in bacterial cell wall-induced arthritis in rats. Gene Ther 1995; 2: 424-8
127. Nita I, Ghivizzani SC, Galealauri J, et al. Direct gene delivery to synovium - an evaluation of potential vectors in vitro and in vivo. Arthritis Rheum 1996; 39: 820-8
128. Roessler BJ, Allen ED, Wilson JM, et al. Adenoviral-mediated gene transfer to rabbit synovium in vivo. J Clin Invest 1993; 92: 1085-92
129. Firestein GS, Nguyen K, Aupperle KR, et al. Apoptosis in rheumatoid arthritis - p53 overexpression in rheumatoid arthritis synovium. Am J Pathol 1996; 149: 2143-51
130. Gay S, Huang G-Q, Ziegler B, et al. Expression of myb, myc, ras and fos oncogenes in synovial cells of patients with rheumatoid arthritis or osteoarthritis [abstract]. Arthritis Rheum 1989; 32 Suppl.: 59
131. Isomaki P, Soderstrom KO, Punnonen J, et al. Expression of bcl-2 in rheumatoid arthritis. Br J Rheumatol 1996; 35: 611-9
132. Roivainen A, Soderstrom KO, Pirila L, et al. Oncoprotein expression in human synovial tissue - an immunohistochemical study of different types of arthritis. Br J Rheumatol 1996; 35: 933-42
133. Roivainen A, Jalava J, Pirila L, et al. H-ras oncogene point mutations in arthritic synovium. Arthritis Rheum 1996; 40: 1636-43
134. Berenblum I. The mechanisms of carcinogenesis - a study of the significance of co-carcinogenic action and related phenomena. Cancer J Clinicians 1981; 31: 241-53
135. Baragi VM, Renkiewicz RR, Jordan H, et al. Transplantation of transduced chondrocytes protects articular cartilage from interleukin 1-induced extracellular matrix degradation. J Clin Invest 1995; 96: 2454-60